INTRODUCTION
where a glycoprotein IIb/IIIa inhibitor has been used, heparin was also used). There are, however, several randomized controlled trials 10) 
MATERIALS AND METHODS

Patients
We retrospectively reviewed all patients with a sub- 
Outcomes and follow-up
Peri-procedural complications and EVD-related 
RESULTS
Patients demographics
Fifty-one aneurysms in 50 patients were treated between April 2012 and March 2016. Among them, nine patients were male (18%) and 41 were female (82%) ( with a grade III, and 28 (56%) with a grade IV.
Twenty-three patients (46%) presented with a WFNS grade I, eight (16%) with a grade II, one (2%) with a grade III, four (8%) with a grade IV, and 14 (28%) with a grade V ( Table 2) . Twenty-four patients (48%) had a history of hypertension, two (4%) a history of
23 (46) 4 (8) 11 (22) 8 (16) Fisher scale 4 (8) 7 (14) 11 (22) 28 (56) WFNS grade 23 (46) 8 (16) 1 (2) 4 (8) 14 (28) Values are presented as number (%). SAH = subarachnoid hemorrhage; H-H grade = Hune-Hess grade; WFNS grade = World Federation of Neurosurgical Societies grade. Values are presented as mean (range) or number (%). M = male; F = female; HTN = hypertension; DM = diabetes mellitus. reported drinking (Table 1) . (Table 3 ).
Aneurysm characteristics
Complications
We divided reported complications between two groups: procedure-related and delayed. We defined (Table 3) . These included 2 hemorrhagic events and 3 thromboembolic events.
EVD-related hemorrhage
Seventeen cases involved EVD catheter insertion.
EVD catheters were inserted in 11 cases prior to SAC and in 6 after SAC. Four (23.5%) EVD-related hemorrhagic events occurred, though all were asymptomatic and none resulted in neurologic deficits. Two of the 4 EVD-related hemorrhage cases underwent EVD insertion before SAC and the other 2 underwent EVD insertion after SAC (Table 4) .
A complicated case
Among all the cases studied here, one was partic- Follow-up angiography 6 months later showed major recanalization of the previously coiled aneurysm.
Retreatment of the recanalized aneurysm was performed ( Fig. 1) . (four patients). Three patients died due to malignant brain swelling and one patient due to pneumonia.
Sixteen (32%) patients had a poor GOS (<4) ( Table 5 ).
Follow-up
The mean duration to final clinical follow-up was 19 months (41 patients). The other nine patients were lost to follow-up due to death or transfer to another hospital. During the follow-up period, eight patients experienced improved GOS ( Table 5 ). The mean duration to angiographic follow-up was 18 months (31 patients). Recanalization of coiled aneurysms was required for two patients upon follow-up. One of these was a minor recanalization while the other was more significant. Retreatment was performed for this major recanalization case.
DISCUSSION
The publication of the randomized controlled When thromboembolic complications do occur, there is an advantage in applying the same substance previously infused intravenously via intra-arterial injection to treat thromboembolisms. Alurkar et al. 2) previously reported two cases with intra-procedural, in-stent thrombosis treated by intra-arterial injection of glycoprotein IIb/IIIa inhibitor without any resultant neurologic deficits. Cho et al. 6) and Kim et al. 15) have also reported on the safety and efficacy of intra-arterial tirofiban injection to treat thromboembolic events during EVT of ruptured aneurysms.
Likewise, when intra-procedural thromboembolic events occurred in the present study cohort, we also obtained good results from the use of intra-arterial tirofiban injection-only five cases of intra-procedure thromboembolic events despite tirofiban use were identified. All of these events comprised in-stent thrombosis, where intra-arterial glycoprotein IIb/IIIa inhibitor injection was done on a case-by-case basis.
When delayed contrast filling occurred due to thrombosis formation in one patient, vessel patency was restored with intra-arterial injection of tirofiban.
Although just one case, this evidences the safety and efficacy of intra-arterial injection of tirofiban.
While there were no cases of intra-procedural aneurysm rupture reported here, it is critical to note that hemorrhagic complications beyond aneurysm re-bleeding may occur with anticoagulant use.
Extra-cranial hemorrhagic complication such as complicated hematoma or gastro-intestinal bleeding may occur. In the present study, there were no cases of complicated hematoma, though one case of upper gastro-intestinal bleeding and one case of delayed intracerebral hemorrhage which was not related to aneurysm were reported. Despite the concern that tirofiban use in the acute phase of SAH may lead to intra-procedural rupture of aneurysms, tirofiban proved to be a relatively safe and efficacious medication for the prevention of thromboembolic complications.
This study has several limitations. First, it uses a retrospective design and is therefore subject to selection bias. Second, it results from data collected at a single center study with a relatively small patient population which does not provide the power to ensure the broader safety and efficacy of tirofiban. 
CONCLUSION
There is concern about the exclusive use of tirofiban to prevent thromboembolic events in stent-assisted coil embolization. However, in the present study, we report the outcomes of ruptured wide-necked intracranial aneurysms treated with SAC with tirofiban alone and conclude that its use is both relatively safe and therapeutically efficient.
